BCLSI
XFOR icon

Bain Capital Life Sciences Investors’s X4 Pharmaceuticals XFOR Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$32.9M Hold
7,967,454
– – 2.97% 7
2025
Q4 		$31.9M Buy
7,967,454
+5,530,866
+227% +$20.1M 2.44% 8
2025
Q3 		$8.33M Buy
2,436,588
+1,872,729
+332% +$4.83M 0.55% 15
2025
Q2 		$1.07M Hold
563,859
– – 0.13% 22
2025
Q1 		$4M Hold
563,859
– – 0.59% 15
2024
Q4 		$12.4M Hold
563,859
– – 1.46% 13
2024
Q3 		$11.3M Hold
563,859
– – 1.18% 13
2024
Q2 		$9.81M Hold
563,859
– – 1.08% 15
2024
Q1 		$23.5M Hold
563,859
– – 1.89% 13
2023
Q4 		$14.2M Buy
563,859
+31,839
+6% +$774K 1.36% 17
2023
Q3 		$17.4M Hold
532,020
– – 1.95% 13
2023
Q2 		$31M Buy
532,020
+125,270
+31% +$6.44M 3.19% 11
2023
Q1 		$10.6M Hold
406,750
– – 1.33% 22
2022
Q4 		$12.1M Buy
406,750
+193,769
+91% +$9.18M 1.35% 20
2022
Q3 		$10.9M Buy
212,981
+112,330
+112% +$3.88M 1.3% 20
2022
Q2 		$2.91M Hold
100,651
– – 0.34% 34
2022
Q1 		$5.28M Buy
100,651
+4,433
+5% +$254K 0.51% 28
2021
Q4 		$6.61M Buy
96,218
+25,567
+36% +$3.23M 0.52% 26
2021
Q3 		$11.2M Hold
70,651
– – 0.7% 23
2021
Q2 		$13.8M Hold
70,651
– – 0.9% 21
2021
Q1 		$18.2M Buy
70,651
+15,701
+29% +$4.13M 1.03% 19
2020
Q4 		$10.6M Hold
54,950
– – 0.67% 20
2020
Q3 		$11.2M Hold
54,950
– – 1.04% 18
2020
Q2 		$15.4M Hold
54,950
– – 1.61% 13
2020
Q1 		$16.5M Hold
54,950
– – 2.79% 8
2019
Q4 		$17.6M Buy
+54,950
New +$19.7M 2.63% 7

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Bain Capital Life Sciences Investors's XFOR Position: Q1 2026 in Review

Bain Capital Life Sciences Investors held its X4 Pharmaceuticals (XFOR) position steady in Q1 2026 at 7,967,454 shares worth $32.9M. The position accounts for 2.97% of the portfolio, ranked #7.

Bain Capital Life Sciences Investors first reported a position in XFOR in Q4 2019 and has held it in 26 quarters since. 84 funds tracked by Wall St. Rank hold XFOR as of Q1 2026.

  • Bain Capital Life Sciences Investors held 7,967,454 shares of X4 Pharmaceuticals worth $32.9M as of Q1 2026.
  • Bain Capital Life Sciences Investors left its X4 Pharmaceuticals share count unchanged in Q1 2026.
  • X4 Pharmaceuticals made up 2.97% of Bain Capital Life Sciences Investors's portfolio in Q1 2026, its #7 holding.
  • Bain Capital Life Sciences Investors first reported a position in X4 Pharmaceuticals in Q4 2019 and has held it in 26 quarters since.
  • 84 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2026.

Based on Bain Capital Life Sciences Investors's 13F filing for Q1 2026, filed 15 May 2026.